Synthetic Fosmidomycin analogues with altered chelating moieties do not inhibit 1-deoxy-d-xylulose 5-phosphate Reductoisomerase or Plasmodium falciparum growth in vitro

Molecules. 2014 Feb 24;19(2):2571-87. doi: 10.3390/molecules19022571.

Abstract

Fourteen new fosmidomycin analogues with altered metal chelating groups were prepared and evaluated for inhibition of E. coli Dxr, M. tuberculosis Dxr and the growth of P. falciparum K1 in human erythrocytes. None of the synthesized compounds showed activity against either enzyme or the Plasmodia. This study further underlines the importance of the hydroxamate functionality and illustrates that identifying effective alternative bidentate ligands for this target enzyme is challenging.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aldose-Ketose Isomerases / antagonists & inhibitors
  • Antimalarials / administration & dosage
  • Antimalarials / chemical synthesis
  • Antimalarials / chemistry
  • Drug Design
  • Enzyme Inhibitors / administration & dosage*
  • Enzyme Inhibitors / chemistry
  • Erythrocytes / drug effects*
  • Fosfomycin / administration & dosage
  • Fosfomycin / analogs & derivatives*
  • Fosfomycin / chemical synthesis
  • Humans
  • Plasmodium falciparum / drug effects*
  • Plasmodium falciparum / growth & development

Substances

  • Antimalarials
  • Enzyme Inhibitors
  • Fosfomycin
  • fosmidomycin
  • 1-deoxy-D-xylulose 5-phosphate reductoisomerase
  • Aldose-Ketose Isomerases